Plocamium Global Insights

Canal, Copper, and Climate at the Western Hemisphere's Most Contested Chokepoint — Three forces are converging on Panama simultaneously: a U.S.-China proxy battle over port infrastructure valued at $22.8 billion, a June 2026 government decision on whether to restart a copper mine that once represented ~2% of global supply, and a structural climate vulnerability that cut canal transits 29% in FY202

Costa Rica became the first Central American nation admitted to the OECD in 2021 — a milestone that required years of regulatory, governance, and transparency reforms. In 2025, the World Bank reclassified it as a high-income country.

In 2024, Mexico became the United States' largest trading partner for the second consecutive year—$840 billion in total trade, the highest annual total any country has ever recorded with the United States.

Geopolitics isn’t a headline risk anymore. It’s an operating variable. As we move through 2025–2026, U.S. healthcare and industrial companies are being shaped less by demand cycles and more by capital constraints, supply-chain exposure, and policy-driven investment. What’s changed is not volatility—it’s the definition of strategy.

In a development few could have predicted even a few years ago, private equity firms are ramping up investments into the defense sector — traditionally considered off-limits for many institutional investors. With Europe planning to spend over €800 billion to rebuild its military capabilities and reduce reliance on U.S. security guarantees, a new landscape is emerging — and private capital inten

One of the most significant effects of the merger will be the integration of both companies’ manufacturing capabilities. Mallinckrodt, historically known for its expertise in specialty branded and generic drugs, brings a portfolio that includes autoimmune treatments, pain management solutions, and ADHD medications. Endo, with a similar focus on pain management through brands like Percocet and Test

Meta’s ongoing discussions with Apollo Global Management to secure a $35 billion financing package for U.S. data centers offer a glimpse into a larger capital cycle—one that extends far beyond tech and into the very fabric of biotech, pharmaceuticals, hospitals, and CDMOs. As AI’s role in healthcare expands, so does the demand for high-performance computing, storage, and network capabilities. The

We’ve long recognized that manufacturing is not just an operational necessity—it is the foundation of sustainable growth, resilience, and innovation. Healthcare companies that embrace this reality will define the future of the industry. Lilly’s announcement is a powerful confirmation of this thesis.

Plocamium has previously discussed energy transition as part of a broader industrial transformation—one that does not operate in isolation but rather converges with advancements in healthcare and manufacturing. Energy security and transition strategies increasingly dictate industrial policy, supply chain resilience, and capital allocation across multiple sectors.

The healthcare industry is undergoing a profound transformation, shaped by stringent regulatory requirements, shifting demographic trends, and the increasing need for outsourced production. Contract development and manufacturing organizations (CDMOs) have emerged as critical players in this evolving landscape, offering pharmaceutical, biotech, and wellness companies the ability to scale efficientl

Manufacturing is no longer just about scale—it's about adaptability. AI-driven drug repurposing is reshaping how CDMOs and CMOs operate, demanding faster, more flexible production cycles that cater to a future where precision trumps volume.

Fosun’s decision to exit Gland Pharma comes at a time when scrutiny of China-dependent supply chains has never been higher. Acquiring Gland Pharma represents more than just buying a profitable CDMO (Contract Development and Manufacturing Organization)—it’s a strategic move to fortify pharma manufacturing outside of China.

Healthcare facilities management is a critical but often underappreciated component of the industry’s infrastructure. Hospitals, clinics, and long-term care facilities rely on effective operations to maintain high-quality patient care, regulatory compliance, and financial efficiency.

In a recent discussion, Lynn Good, CEO of Duke Energy, offered a strategic perspective on the latest round of proposed tariffs. Rather than viewing them as purely protectionist, Good framed them as a negotiation tool designed to reshape global trade dynamics. Her analysis highlighted the industries that stand to benefit, those that will face headwinds, and the broader implications for economic pol

The climate-tech sector is undergoing a massive shift, with M&A leading the charge. Last year alone, we saw nearly $80 billion in climate-tech deals across more than 300 transactions, with over 60% focused on clean power and energy storage.

Novartis’ recent $3.1 billion acquisition of Anthos Therapeutics is more than just a transaction—it’s a strategic pipeline reintegration move that could signal a new era in biopharma M&A. The deal brings abelacimab, a promising Factor XI inhibitor for stroke prevention, back under Novartis’ control after it was spun out to Anthos, a Blackstone-backed biotech, in 2019

How the Trump administration's deregulation push could reshape healthcare policy, from Medicaid home-health rules to private equity investment opportunities in the sector.

France is making a high-stakes move in the global AI race, announcing a staggering €109 billion in AI investments. This initiative, championed by President Emmanuel Macron, isn’t just about economic growth—it’s about geopolitics, sovereignty, and Europe’s place in the artificial intelligence arms race.

This isn’t just another healthcare technology deal—it’s a microcosm of how today’s private markets are pushing the boundaries of leverage and financial structuring. But the key question remains: Is this the right kind of leverage?

Pfizer Inc. (NYSE: PFE) stands at a financial crossroads, balancing its capital allocation priorities between business development (BD), debt management, and shareholder returns.

Drones The Syracuse-based defense technology startup recently secured $100 million in funding across two rounds, propelling its valuation to nearly $500 million. With strategic backing from DFJ Growth and Lockheed Martin Ventures, Hidden Level is now positioned to scale its passive radar technology, a breakthrough system capable of tracking aerial threats without emitting a detectable signal.

Amazon’s $16 billion data center investment in Mississippi is making headlines—but not for the reasons you might think. Amazon’s $16 billion data center investment in Mississippi is making headlines—but not for the reasons you might think.

Yet, while the geopolitical stakes are clear, what’s often overlooked is the financial and industrial opportunity emerging from this technological race. This isn’t just a defense story; it’s an investment story.

For decades, there was a persistent belief that China’s role in the global tech ecosystem was to follow, not lead. Chinese companies were often accused of replicating Western innovations rather than pioneering their own. But today, that narrative is outdated.

With AI innovation moving fast, protecting proprietary technology is more critical than ever. The outcome of this probe could reshape the global AI landscape.